RNAi-based nanomedicines for targeted personalized therapy

RNA interference (RNAi) has just made it through the pipeline to clinical trials. However, in order for RNAi to serve as an ideal personalized therapeutics and be clinically approved—safe, specific, and potent strategies must be devised for efficient delivery of RNAi payloads to specific cell types,...

Full description

Saved in:
Bibliographic Details
Published in:Advanced drug delivery reviews 2012-10, Vol.64 (13), p.1508-1521
Main Authors: Daka, Ala, Peer, Dan
Format: Article
Language:English
Subjects:
Animals
Clinical trials
Humans
In vivo
Nanomedicine
Nanoparticles
Nanoparticles - administration & dosage
Personalized medicine
Precision Medicine
RNA Interference
RNA, Small Interfering - administration & dosage
Short interfering RNA (siRNA)
Systemic delivery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:RNA interference (RNAi) has just made it through the pipeline to clinical trials. However, in order for RNAi to serve as an ideal personalized therapeutics and be clinically approved—safe, specific, and potent strategies must be devised for efficient delivery of RNAi payloads to specific cell types, which despite the immense potential, remains a challenge. Through evaluating the recent reported studies in this field, we introduce the progress in designing targeted nano-scaled strategies that are anticipated to overcome the delivery drawbacks and along with the exciting “omics” discipline to personalize RNAi-based therapeutics. [Display omitted]
ISSN:0169-409X
1872-8294
DOI:10.1016/j.addr.2012.08.014